Calidi Biotherapeutics Inc
CLDI1.380USD
+0.070+5.34%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
9.53MMarket Cap
4.25P/E TTM
More Details of Calidi Biotherapeutics Inc Company
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Calidi Biotherapeutics Inc Info
Ticker SymbolCLDI
Company nameCalidi Biotherapeutics Inc
IPO dateSep 10, 2021
CEOPoma (Eric)
Number of employees28
Security typeOrdinary Share
Fiscal year-endSep 10
Address4475 Executive Drive, Suite 200
CitySAN DIEGO
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code92121
Phone18587949600
Websitehttps://www.calidibio.com/
Ticker SymbolCLDI
IPO dateSep 10, 2021
CEOPoma (Eric)
Company Executives of Calidi Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Scott Leftwich
Mr. Scott Leftwich
Independent Director
Independent Director
146.63K
+577.97%
Mr. James A. Schoeneck
Mr. James A. Schoeneck
Independent Chairman of the Board
Independent Chairman of the Board
84.51K
+788.59%
Mr. Andrew C. Jackson
Mr. Andrew C. Jackson
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
2.50K
--
Mr. Alan R. Stewart
Mr. Alan R. Stewart
Independent Director
Independent Director
2.42K
+0.08%
Mr. Allan J. Camaisa
Mr. Allan J. Camaisa
Independent Director
Independent Director
--
--
Col. (Retd.) George E. Peoples, Jr., M.D.
Col. (Retd.) George E. Peoples, Jr., M.D.
Independent Director
Independent Director
--
--
Dr. Eric Poma, Ph.D.
Dr. Eric Poma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Travis Clifton, M.D.
Dr. Travis Clifton, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Scott Leftwich
Mr. Scott Leftwich
Independent Director
Independent Director
146.63K
+577.97%
Mr. James A. Schoeneck
Mr. James A. Schoeneck
Independent Chairman of the Board
Independent Chairman of the Board
84.51K
+788.59%
Mr. Andrew C. Jackson
Mr. Andrew C. Jackson
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
2.50K
--
Mr. Alan R. Stewart
Mr. Alan R. Stewart
Independent Director
Independent Director
2.42K
+0.08%
Mr. Allan J. Camaisa
Mr. Allan J. Camaisa
Independent Director
Independent Director
--
--
Col. (Retd.) George E. Peoples, Jr., M.D.
Col. (Retd.) George E. Peoples, Jr., M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
10.18%
Leftwich (Scott)
2.05%
Hightower Advisors, LLC
1.19%
Schoeneck (James A)
1.18%
Jamir Trust
0.71%
Other
84.70%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
10.18%
Leftwich (Scott)
2.05%
Hightower Advisors, LLC
1.19%
Schoeneck (James A)
1.18%
Jamir Trust
0.71%
Other
84.70%
Shareholder Types
Shareholders
Proportion
Corporation
11.22%
Individual Investor
4.22%
Investment Advisor
1.93%
Investment Advisor/Hedge Fund
1.02%
Hedge Fund
0.28%
Bank and Trust
0.04%
Other
81.29%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
68
234.15K
3.83%
--
2025Q3
71
235.29K
4.99%
-4.61K
2025Q2
85
239.90K
18.88%
-216.94K
2025Q1
87
456.83K
4.48%
+328.01K
2024Q4
83
93.50K
4.14%
+64.96K
2024Q3
76
28.55K
6.89%
+5.09K
2024Q2
94
23.45K
20.62%
-389.00
2024Q1
92
23.84K
40.53%
-96.18K
2023Q4
87
22.63K
44.48%
+7.71K
2023Q3
76
14.91K
50.69%
-18.65K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lincoln Alternative Strategies LLC
730.00K
13.27%
+730.00K
--
Aug 20, 2025
Leftwich (Scott)
146.63K
2.67%
+125.00K
+577.97%
Aug 21, 2025
Hightower Advisors, LLC
9.96K
0.18%
--
--
Jun 30, 2025
Schoeneck (James A)
84.51K
1.54%
+75.00K
+788.59%
Aug 21, 2025
Jamir Trust
50.81K
0.92%
+107.00
+0.21%
Aug 08, 2025
Belpointe Asset Management LLC
20.82K
0.38%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
29.45K
0.54%
--
--
Jun 30, 2025
Kessler (Judd S)
31.08K
0.57%
+31.08K
--
May 01, 2024
Geode Capital Management, L.L.C.
19.38K
0.35%
-1.61K
-7.68%
Jun 30, 2025
Poma (Eric E. Ph.D.)
25.00K
0.45%
+25.00K
--
Aug 21, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 25, 2025
Merger
12→1
Jul 05, 2024
Merger
10→1
Jul 05, 2024
Merger
10→1
Jul 05, 2024
Merger
10→1
Jul 05, 2024
Merger
10→1
Date
Type
Ratio
Jul 25, 2025
Merger
12→1
Jul 05, 2024
Merger
10→1
Jul 05, 2024
Merger
10→1
Jul 05, 2024
Merger
10→1
Jul 05, 2024
Merger
10→1
FAQs
Who are the top five shareholders of Calidi Biotherapeutics Inc?
The top five shareholders of Calidi Biotherapeutics Inc are:
Lincoln Alternative Strategies LLC holds 730.00K shares, accounting for 13.27% of the total shares.
Leftwich (Scott) holds 146.63K shares, accounting for 2.67% of the total shares.
Hightower Advisors, LLC holds 9.96K shares, accounting for 0.18% of the total shares.
Schoeneck (James A) holds 84.51K shares, accounting for 1.54% of the total shares.
Jamir Trust holds 50.81K shares, accounting for 0.92% of the total shares.
Lincoln Alternative Strategies LLC holds 730.00K shares, accounting for 13.27% of the total shares.
Leftwich (Scott) holds 146.63K shares, accounting for 2.67% of the total shares.
Hightower Advisors, LLC holds 9.96K shares, accounting for 0.18% of the total shares.
Schoeneck (James A) holds 84.51K shares, accounting for 1.54% of the total shares.
Jamir Trust holds 50.81K shares, accounting for 0.92% of the total shares.
What are the top three shareholder types of Calidi Biotherapeutics Inc?
The top three shareholder types of Calidi Biotherapeutics Inc are:
Lincoln Alternative Strategies LLC
Leftwich (Scott)
Hightower Advisors, LLC
Lincoln Alternative Strategies LLC
Leftwich (Scott)
Hightower Advisors, LLC
How many institutions hold shares of Calidi Biotherapeutics Inc (CLDI)?
As of 2025Q4, 68 institutions hold shares of Calidi Biotherapeutics Inc, with a combined market value of approximately 234.15K, accounting for 3.83% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.16%.
What is the biggest source of revenue for Calidi Biotherapeutics Inc?
In --, the -- business generated the highest revenue for Calidi Biotherapeutics Inc, amounting to -- and accounting for --% of total revenue.
